- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05235490
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma (LIVERIBIOPSY)
Tumor recurrence, which occurs in 70% of patients with HCC within 5 years after hepatic resection, is a major cause of post-resection-death. This recurrence can be true recurrence (intrahepatic metastases), which occurs sooner than 2 years later, or it can be due to the development of de-novo tumors at least 2 years later. Despite this high rate of tumor recurrence, no anti-recurrence adjuvant therapies are currently recommended.
Imaging phenomics is the systematic, large scale extraction of imaging features for the characterization and classification of disease phenotypes. Combining imaging and tissue phenomics could be a solution to predict HCC recurrence. With the emergence of molecular therapies and immunotherapies, identifying patients with HCC at high risk of post-resection recurrence would help determine additional therapeutic and management strategies in clinical practice.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
Hepatocellular carcinoma (HCC) is among the most lethal and prevalent cancers in the human population and it is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. Because of the high recurrence rate after curative hepatectomy, accurate prognostic assessment in HCC patients are quite important. With the emergence of molecular therapies and immunotherapies, the identification of patients at high or low risk for recurrence after hepatic resection would help determine additional therapeutic and management strategies in clinical practice. Although many immunohistochemical markers have been reported to have a prognostic value for HCC patients, there is no consensus on how these markers could add prognostic value to the clinical parameters.
In the initial step of biomarker discovery, no specific sample size is provided, however to test hypothesis, 100 patients are required.
This first study will potentially be followed by a second similar study promoted by the same investigators to increase the statistical power to improve the classification tool according to the patient's future.
Period covered by the data collection: 2011-2019 / Duration data collection: 1 year.
The primary endpoint will be built using machine learning method to obtain prediction of recurrence within 2 years. The Recurrence Free survival (RFS) within two years will be the reference outcome to evaluate the prognostic of the patients.
The secondary endpoint are following :
- A secondary endpoint which will be built using machine learning method to obtain prediction of recurrence after 2 years.
The Recurrence Free survival (RFS) after two years will be the reference outcome to evaluate the prognostic of the patients.
- A secondary endpoint will be the correlation between biomarker from CT scan and pathological biomarkers As the spectrum of HCC disease is very large, many patients to conduct conclusive validation studies for diagnostic and prognostic relevance need to be obtained.
Overall, each specific-read out endpoint will include a sample size calculation and - if appropriate - a power analysis specific to the objective of this study.
During training, phenotyping system performance assessment will be done to guide the calculation of the sample size for the validation.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Villejuif, Francia, 94800
- Paul Brousse Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age ≥ 18 years old
- Patients who underwent surgery and have R0 resection after 2010
- Multiphase CT scans with contrast media should be performed within 2 months prior to surgical intervention
- At least 2 years of follow-up data on intrahepatic recurrence
Exclusion Criteria:
- Previous HCC treatment
- Combination of other anti-cancer treatment
- Other malignancies
- Patient expressly expressing opposition to the exploitation of their data as defined by the project
- Protected adults
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
The main objective of this work is to identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for an early recurrence in patients with hepatocellular cancer.
Lasso di tempo: 2 years
|
The primary endpoint will be built using machine learning method to obtain prediction of recurrence within 2 years.
The Recurrence Free survival (RFS) within two years will be the reference outcome to evaluate the prognostic of the patients.
|
2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Identify biomarkers from CT scan (non-invasive imaging phenotypes from radiological images) which have a prognostic value for a tardive recurrence in patients with hepatocellular cancer.
Lasso di tempo: 2 years
|
A secondary endpoint which will be built using machine learning method to obtain prediction of recurrence after 2 years.
The Recurrence Free survival (RFS) after two years will be the reference outcome to evaluate the prognostic of the patients.
|
2 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
To correlate the imaging signatures predictive of recurrence with the cell population molding of tissue microenvironment (TME) and the tumor biology using tissue assessment as reference.
Lasso di tempo: 1 year
|
Correlation between biomarker from CT scan and nodule size, nodule differentiation (grade OMS), nodule capsule, macroscopie invasion, microscopic vascular invasion, macrotrabecular sub-type, satellite nodule, staging.
|
1 year
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Maïté LEWIN, Professor, Paul Brousse Hospital
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Processi patologici
- Neoplasie per tipo istologico
- Neoplasie
- Neoplasie per sede
- Adenocarcinoma
- Neoplasie, ghiandolari ed epiteliali
- Attributi della malattia
- Neoplasie dell'apparato digerente
- Malattie del fegato
- Neoplasie del fegato
- Carcinoma
- Carcinoma, epatocellulare
- Ricorrenza
Altri numeri di identificazione dello studio
- APHP191113
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Non intervention
-
University of PittsburghReclutamentoDistrofia muscolare di DuchenneStati Uniti
-
Sarah MorrowLawson Health Research InstituteCompletato
-
University of TulsaTerminatoSuicidio, tentatoStati Uniti
-
Lisbon Institute of Global Mental Health - LIGMHColumbia UniversityReclutamentoDisturbi psicotici | Schizofrenia | Disordine bipolare | Disturbo affettivo schizoidePortogallo
-
Indiana UniversityUniversity of South Florida; National Institute on Minority Health and Health... e altri collaboratoriCompletatoIntervento DECIDE modificato | Trattamento come consueto gruppo di curaStati Uniti
-
University of MichiganNational Institute on Drug Abuse (NIDA)ReclutamentoUso di cannabisStati Uniti
-
Icahn School of Medicine at Mount SinaiReclutamento
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)ReclutamentoProfilassi pre-esposizione all'HIVStati Uniti
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgSconosciuto
-
Stanford UniversityCompletato